Posts by tag
clinical trials
Daraxonrasib: A Turning Point for Pancreatic Cancer
Pancreatic ductal adenocarcinoma remains one of the most difficult cancers to treat, with limited progress in drug development over the past decade. At the 2026 ASCO Annual Meeting, the Phase 3 RASolute 302 trial delivered results that stood out against…
The Ovation and the Asterisk
Five trials, five cancers, and what the ASCO 2026 plenary really promised patients ASCO 2026’s plenary delivered five real advances across five cancers, and a standing ovation that pulled a hall full of oncologists to their feet. The harder question…
Rewriting RAS: A New Targeted Option on the Horizon for Pancreatic Cancer
Metastatic pancreatic cancer remains one of the most treatment-refractory solid tumours in oncology. Despite multiple incremental refinements over the past decade, first-line therapy continues to rely on cytotoxic chemotherapy, most commonly FOLFIRINOX or gemcitabine plus nab-paclitaxel, with limited change in…
Michael Gnant at the Crossroads of Oncology: Precision, Restraint, and the Courage to Challenge Orthodoxy
Sixteen years ago, Dr. Michael Gnant was portrayed in CancerWorld as a surgical oncologist unafraid to push boundaries in breast cancer care. Today, his perspective reflects not retreat but evolution. The boundary-pusher remains, but his focus has widened. His work…
Making Sense of a Decade of Progress in Advanced Breast Cancer: ABC8, Lisbon 2025
The 8th ABC International Consensus Conference (ABC8), Lisbon 2025 Over the past decade, the landscape of advanced breast cancer has changed more rapidly than at any time since systemic therapy became standard. New drug classes, more refined biomarkers, and increasingly…
Rethinking Immunotherapy for Pancreatic Cancer: A Universal Approach
Chimeric antigen receptor natural killer T (CAR-NKT) cell therapy, a novel form of immunotherapy, is emerging as a promising ‘off-the-shelf’ treatment for patients with pancreatic cancer. In a study published in PNAS, November 21, 2025, U.S. investigators report that CAR-NKT cells…
Gentle with People. Precise with Cancer.
Each evening, after a day leading one of Italy’s busiest radiotherapy departments, Prof. Andrea Filippi, Head of the Radiation Oncology Unit at the Istituto Nazionale dei Tumori in Milan, and the Associate Professor of Radiation Oncology in the Department of…
Common Sense Oncology: Putting Patients Back at the Center in the Era of Cancer Innovation
Precision medicine, immunotherapy, and cellular therapies have reshaped the landscape of oncology, turning once-fatal diagnoses into chronic, or even curable, conditions. These breakthroughs represent extraordinary scientific progress and a deepening understanding of cancer biology. Yet beneath this success runs a…
She’s Gone and Done It: The Story of Dr. Nageatte Ibrahim
Dr. Nageatte Ibrahim has spent her career at the intersection of oncology, science, and medicine, with achievements resulting in global impacts. Trained as a physician and scientist, she played a central role in the development of Keytruda, one of the…
Curious, Rejected,Accepted: An ESO Fellow’s Road to Becoming an Oncologist
It was 2018, and I was a fifth-year medical student at Yerevan State Medical University. Word spread that our new oncology professor was someone extraordinary: Gevorg Tamamyan - a Harvard-trained, Nature-published pioneer of pediatric oncology in Armenia and president of…